Search

Search Constraints

You searched for: Author/Creator Kaibori, Masaki

Search Results

1. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022)

2. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)

3. Cinnamomi Cortex and Scutellariae Radix in the Japanese herbal medicine Kampo saireito inhibit expression of iNOS through different mechanisms in hepatocytes. Issue 1 (25th February 2020)

4. Clinical impact of laparoscopic surgery and adhesion prevention material for prevention of small bowel obstruction. Issue 5 (18th March 2022)

5. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines). Issue 5 (10th March 2023)

6. Comparison of anatomic and non‐anatomic hepatic resection for hepatocellular carcinoma. (19th October 2017)

7. Comparison of Tc-99m GSA scintigraphy and CT volumetry for evaluation in portal vein embolization. Issue 4 (August 2014)

8. Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib. (3rd June 2022)

10. Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. (17th September 2021)